Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Conditions
Glioblastoma Multiforme
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Southern California, Los Angeles, California, United States
Contact: Principal Investigator (Frances Chow, MD)Saint John Cancer Institute, Santa Monica, California, United States
Contact: Principal Investigator (Naveed Wagle, MD)Georgia Cancer Center (Augusta University), Augusta, Georgia, United States
Contact: Principal Investigator (Gerald Wallace)Ochsner Health, New Orleans, Louisiana, United States
Contact: Principal Investigator (Caroline Goldin)Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
Contact: Principal Investigator (Robert Aiken)Northwell Health, New York, New York, United States
Contact: Principal Investigator (Samuel Singer)Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Contact: Principal Investigator (David Peereboom, MD)Baylor Scott & White Health, Dallas, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Noah Puente)University of Washington Medical Center, Seattle, Washington, United States
Contact: Study coordinator (Maciej Mrugala)University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States
Contact: Study coordinator (Steve Howard, MD)
Study leads
Thomas Chen, MD, PhD
Study Chair
NeOnc Technologies Holdings, Inc.
Josh Neman, PhD
Study Director
NeOnc Technologies Holdings, Inc.